Market Place
Sourcing Support
SpringWorks Publishes Phase 2b ReNeu Results in Clinical Oncology
11 Nov 2024 //
GLOBENEWSWIRE
SpringWorks Submits NDA For Mirdametinib In NF1-PN Treatment
01 Jul 2024 //
GLOBENEWSWIRE
Springworks Data Presentation: 2024 Asco Annual Meeting Scheduled
23 May 2024 //
GLOBENEWSWIRE
SpringWorks Abstracts Accepted for ASCO 2024 Presentation
24 Apr 2024 //
GLOBENEWSWIRE
SpringWorks Initiates Rolling Submission of NDA to the FDA for Mirdametinib
04 Mar 2024 //
GLOBENEWSWIRE
SpringWorks Announces Positive Results from Phase 2b ReNeu Trial of Mirdametinib
16 Nov 2023 //
GLOBENEWSWIRE
BeiGene & SpringWorks Present Clinical Data Lifirafenib, in ComBO Mirdametinib
17 Apr 2023 //
BUSINESSWIRE
SpringWorks & BeiGene Present Clinical Data on Lifirafenib, combo Mirdametinib
17 Apr 2023 //
GLOBENEWSWIRE
SpringWorks Announces Initiation of Ph 1/2 Clinical Trial of Mirdametinib
16 Jun 2021 //
GLOBENEWSWIRE
SpringWorks Reports Interim Data from Phase 2b ReNeu Trial of Mirdametinib
25 Feb 2021 //
SPRINGLINK
SpringWorks Announces of Phase 1b Clinical Trial of MEK Inhibitor PD-0325901
06 May 2019 //
BUSINESSWIRE
SpringWorks names a CEO, inks a combo therapy deal with BeiGene
06 Sep 2018 //
FIERCE BIOTECH
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.